Pharma News

OrigAMI-4 study shows strong tumor responses in patients with recurrent or metastatic head and neck cancer after standard treatments fail. Johnson & Johnson has announced promising clinical results for its investigational therapy RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) in patients with advanced head and neck squamous cell carcinoma (HNSCC), a disease where treatment options remain limited once standard therapies stop working.

Atherosclerosis, the gradual buildup of fatty deposits inside arteries, remains one of the leading causes of heart attacks and strokes worldwide. While inflammation has long been recognized as a major contributor to the disease, new research from scientists at Ludwig Maximilian University of Munich suggests that certain inflammatory immune cells may also play a protective role in slowing its progression.

Medicines commonly prescribed to treat anemia in patients with chronic kidney disease may have an unexpected role in cancer therapy, according to a new study from Finland. Researchers have found that a class of anemia drugs known as HIF-prolyl hydroxylase inhibitors (HIF-PHIs) can interfere with cancer-related processes, potentially helping patients manage both anemia and tumor progression at the same time.

Shares of Indoco Remedies gained 4.12% on Friday after the company announced that its Oral Solid Dosage (OSD) manufacturing facility at Baddi, Himachal Pradesh, has received European Union Good Manufacturing Practice (EU GMP) certification from the German Health Authority, Berlin. The regulatory approval is expected to strengthen the company's position in regulated European markets and has been welcomed positively by investors.

Global biotechnology company Regeneron Pharmaceuticals has announced plans to establish its first Global Capability Centre (GCC) outside the United States in Hyderabad, further strengthening Telangana's position as a leading destination for global life sciences and technology investments.

Wockhardt has received marketing authorization from India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), for its breakthrough antibiotic ZAYNICH® (Zidebactam/Cefepime). The approval marks a significant milestone for India’s fight against antimicrobial resistance, especially in difficult-to-treat Gram-negative bacterial infections.

Mumbai-based Sun Pharmaceutical Industries Limited has announced that it will present updated long-term clinical data for UNLOXCYT™ (cosibelimab-ipdl) at the upcoming ASCO Annual Meeting in Chicago. The presentation will focus on patients suffering from locally advanced cutaneous squamous cell carcinoma (laCSCC), a serious form of skin cancer.